Physician profile
Pavan Nataraj
NPI 1508359035
$4,177.06
in general payments reported to CMS, 2019-2025
25 companies · $2,565 in 2025
The $2,565 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2022: $132 · 2023: $109 · 2024: $1,020 · 2025: $2,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,615 · Education: $46.40 · Consulting Fee: $32.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,614.59 |
| Education | $46.40 |
| Consulting Fee | $32.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,048.57 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $665.73 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $374.70 | 2025 | |
| Amgen INC. | $285.22 | 2024-2025 | Tezspire |
| Genentech USA, INC. | $270.76 | 2025 | Xolair |
| Glaxosmithkline, LLC. | $210.36 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.93 | 2024-2025 | Cuvitru, Takhzyro |
| E.R. Squibb & Sons, L.L.C. | $121.62 | 2019 | |
| Optinose US, INC. | $109.41 | 2024-2025 | |
| Blueprint Medicines Corporation | $108.66 | 2023 | |
| Amarin Pharma, INC. | $105.00 | 2019 | |
| Lilly USA, LLC | $85.48 | 2024 | |
| Pfizer INC. | $81.31 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $81.02 | 2025 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $68.26 | 2025 | Neffy |
| Grifols USA, LLC | $57.99 | 2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $57.80 | 2024-2025 | Hizentra |
| Arcutis Biotherapeutics, INC. | $44.20 | 2025 | Zoryve |
| Adma Biomanufacturing LLC | $32.58 | 2025 | |
| Alk-Abello, INC | $31.60 | 2025 | Pre-Pen, Alternaria Tenuis, Standardized Mite D. Farinae |
| Ionis Pharmaceuticals, INC. | $26.17 | 2025 | Dawnzera |
| Leo Pharma INC. | $22.20 | 2025 | Anzupgo |
| Hikma Pharmaceuticals USA | $21.27 | 2025 | Ryaltris |
| Phadia US INC. | $20.22 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Nataraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.